Noubar Afeyan, a director at Moderna, Inc. (NASDAQ:MRNA), engaged in a notable transaction involving company stock as detailed in a recent SEC Form 4 filing. On May 21, 2026, Mr. Afeyan disposed of common shares totaling $433,878. This sale was executed through the disposition of 9,263 shares, with each share priced at $46.84.
The timing of this sale is noteworthy given that Moderna's stock has seen substantial appreciation, trading at $46.88, which represents a rise of 75% over the preceding year. Despite this upward trend, an analysis provided by InvestingPro suggests that the company's current valuation may be elevated when compared to its calculated Fair Value.
The stock sale was directly linked to Mr. Afeyan exercising options on the same date. Specifically, Flagship Pioneering, LLC, utilized these options to purchase 9,263 shares of Moderna’s common stock at a rate of $19.15 per share. This option exercise resulted in an initial acquisition value of $177,386.
These particular options were set to expire on August 10, 2026, and the filing indicated that they were fully vested and exercisable. It is important to note that the securities involved in both this option exercise and the subsequent sale are held indirectly by Flagship Pioneering, LLC.
Regarding beneficial ownership, Mr. Afeyan is identified as the ultimate control person of Flagship Pioneering, LLC. However, he explicitly disclaims beneficial ownership over these shares, except to the extent that such ownership relates to his pecuniary interest in the company.
The transaction affected Mr. Afeyan's indirect holdings through Flagship Pioneering, LLC, which subsequently decreased to 3,924 shares. Furthermore, Mr. Afeyan maintains substantial indirect stakes in other entities. These include an indirect holding of 3,880,328 shares via Flagship Ventures Fund IV, L.P., and another indirect stake of 747,897 shares through Flagship Ventures Fund IV-Rx, L.P.. In both instances, he also disclaims beneficial ownership except for his pecuniary interest.
In addition to these indirect holdings, Mr. Afeyan holds a direct position of 2,224,015 shares in Moderna's common stock.
Risks
- Valuation risk: InvestingPro suggests Moderna stock is overvalued relative to its Fair Value, despite strong price appreciation.
- Market timing risk: The sale occurred while the stock was trading at a high level (75% increase in one year), suggesting potential profit-taking by insiders.
- Regulatory/Legal Risk: The recent amendment of bylaws designating federal district courts as exclusive forum could impact legal strategy and litigation costs.
More from Insider Trading
Risks
- Valuation risk: InvestingPro suggests Moderna stock is overvalued relative to its Fair Value, despite strong price appreciation.
- Market timing risk: The sale occurred while the stock was trading at a high level (75% increase in one year), suggesting potential profit-taking by insiders.
- Regulatory/Legal Risk: The recent amendment of bylaws designating federal district courts as exclusive forum could impact legal strategy and litigation costs.